• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by MeiraGTx Holdings plc

    1/2/26 4:20:05 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MGTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 7)


    MeiraGTx Holdings plc

    (Name of Issuer)


    Ordinary Shares, nominal value $0.00003881 per share

    (Title of Class of Securities)


    G59665102

    (CUSIP Number)


    Alexander Rakitin
    Perceptive Advisors LLC, 51 Astor Place, 10th Floor
    New York, NY, 10003
    (646) 205-5345

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    12/31/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    G59665102


    1 Name of reporting person

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    10,441,562.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    10,441,562.00
    11Aggregate amount beneficially owned by each reporting person

    10,441,562.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.9 %
    14Type of Reporting Person (See Instructions)

    IA



    SCHEDULE 13D

    CUSIP No.
    G59665102


    1 Name of reporting person

    Joseph Edelman
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    10,441,562.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    10,441,562.00
    11Aggregate amount beneficially owned by each reporting person

    10,441,562.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.9 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    G59665102


    1 Name of reporting person

    Perceptive Life Sciences Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    10,441,562.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    10,441,562.00
    11Aggregate amount beneficially owned by each reporting person

    10,441,562.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.9 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Ordinary Shares, nominal value $0.00003881 per share
    (b)Name of Issuer:

    MeiraGTx Holdings plc
    (c)Address of Issuer's Principal Executive Offices:

    450 East 29th Street, 14th Floor, New York, NEW YORK , 10016.
    Item 5.Interest in Securities of the Issuer
    (a)
    Items 5(a)-(c) of the Schedule 13D are amended and supplemented as follows: The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentages set forth in row 13 are based on 80,490,889 outstanding Ordinary Shares as of October 28, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2025, and give effect to the exercise of 115,459 vested stock options and 95,000 shares issuable upon the settlement of deferred share units that the Advisor has rights to pursuant to a management fee offset, as described below.
    (b)
    The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. Ellen Hukkelhoven, the Head of Investment Research of the Advisor, holds (i) stock options exercisable for a total of 115,459 Ordinary Shares, all of which are currently exercisable, and (ii) 140,000 deferred share units, of which 95,000 have vested or will vest within 60 days.
    (c)
    On December 31, 2025, the Master Fund sold 2,300,000 Ordinary Shares to the Issuer at a price per share of $7.91 pursuant to the Share Purchase Agreement (as defined in Item 6 below). Item 6 of the Schedule 13D is incorporated by reference. Except as described herein, none of the Reporting Persons has effected any transaction in the Ordinary Shares in the past 60 days.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Item 6 of the Schedule 13D is amended and supplemented as follows: On December 31, 2025, the Master Fund entered into a share purchase agreement (the "Share Purchase Agreement") with the Issuer, pursuant to which the Issuer agreed to purchase 2,300,000 Ordinary Shares from the Master Fund at a price of $7.91 per share (which was the volume-weighted average price (VWAP) per share on the Nasdaq Global Select Market on December 31, 2025), for an aggregate purchase price of $18,193,000 (the "Share Repurchase"). The transaction contemplated by the Share Purchase Agreement is expected to close on January 5, 2026. Pursuant to the terms of the Share Purchase Agreement, the Master Fund agreed that it and its affiliates will not, without the Issuer's prior written consent, sell, transfer or dispose of any Ordinary Shares (the "Lock-Up Securities"), or any securities convertible into or exercisable or exchangeable for the Ordinary Shares, or otherwise make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale of the Lock-Up Securities, until twelve (12) months from the closing date of the Share Repurchase, provided that the foregoing restriction does not prohibit (a) the Master Fund from transferring any Lock-Up Securities to the Issuer or any transfers contemplated by the Securities Purchase Agreement, including the Share Repurchase; or (b) the disposition of Lock-Up Securities pursuant to (i) any merger, consolidation or similar transaction to which the Issuer is a constituent corporation, (ii) a bona fide tender offer or exchange offer made to all of the holders of capital stock by a person or entity other than the Master Fund (or any of its affiliates or any person or entity acting on behalf of or as part of a group or in concert with the Master Fund or any of its affiliates), (iii) to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the Master Fund, or to any investment fund or other entity controlling, controlled by, managing or managed by the Master Fund or affiliates of the Master Fund, or (iv) as part of a distribution, transfer or disposition by the Master Fund to the Master Fund's stockholders, current or former partners (general or limited), members, beneficiaries or other equity holders, or to the estates of any such stockholders, partners, beneficiaries or other equity holders. The foregoing description of the Share Purchase Agreement is qualified in its entirety by reference to the full text of the agreement, a copy of which is included as Exhibit 6 hereto.
    Item 7.Material to be Filed as Exhibits.
     
    Item 7 of the Schedule 13D is amended and supplemented as follows: Exhibit 6 Share Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 2, 2026)

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:01/02/2026
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman
    Date:01/02/2026
     
    Perceptive Life Sciences Master Fund, Ltd.
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:01/02/2026
    Get the next $MGTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGTX

    DatePrice TargetRatingAnalyst
    11/24/2025$20.00Buy
    H.C. Wainwright
    10/21/2025$29.00Strong Buy
    Raymond James
    7/31/2024$36.00Buy
    Chardan Capital Markets
    More analyst ratings

    $MGTX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by MeiraGTx Holdings plc

    SCHEDULE 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)

    1/2/26 4:20:05 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Holdings plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - MeiraGTx Holdings plc (0001735438) (Filer)

    1/2/26 8:02:20 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by MeiraGTx Holdings plc

    SCHEDULE 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

    11/13/25 9:05:15 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference

    NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and central nervous system disorders, among other therapeutic indications, today announced that Samuel Waksal, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore HealthCONx Conference. Details of the fireside chat are as follows: Tuesday, December 2, 2025 at 8:45am Eastern TimeThe fireside chat will provide an overview of Graviton's obesity research program and selective ROCK2 inhibitor development, highlighting: Target Biology. ROCK2 (Rho-associated coiled-coil

    11/20/25 3:00:00 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

    Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) Released material under the Company's Specials license for a second rare pediatric ophthalmology condition caused by mutations in BBS10, with the prescribing physician treating the first patient during the quarter. The BBS10 program has been awarded Rare Pediatric Disease Designation (RPDD) LONDON and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integr

    11/13/25 8:00:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

    LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly and Company ("Lilly"). MeiraGTx will grant Lilly worldwide exclusive rights to its AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) owing to genetic deficiency of Aryl-hydrocarbon-interacting protein-like 1 (AIPL1). Clinical data from 11 children under the age of 4 who were born legally blind as a result of mutations in the AIPL1 gene were unprecedented, with all 11 blind c

    11/10/25 7:00:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on MeiraGTx with a new price target

    H.C. Wainwright initiated coverage of MeiraGTx with a rating of Buy and set a new price target of $20.00

    11/24/25 8:18:26 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James initiated coverage on MeiraGTx with a new price target

    Raymond James initiated coverage of MeiraGTx with a rating of Strong Buy and set a new price target of $29.00

    10/21/25 7:21:05 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital Markets resumed coverage on MeiraGTx with a new price target

    Chardan Capital Markets resumed coverage of MeiraGTx with a rating of Buy and set a new price target of $36.00

    7/31/24 6:30:53 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Perceptive Advisors Llc bought $5,000,000 worth of Ordinary Shares (1,250,000 units at $4.00) (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    8/14/24 6:54:38 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Zeldin Robert K converted options into 17,500 units of Ordinary Shares and covered exercise/tax liability with 6,729 units of Ordinary Shares, increasing direct ownership by 8% to 147,291 units (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    1/8/26 9:03:09 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GENERAL COUNSEL AND SECRETARY Wollin Robert J converted options into 7,500 units of Ordinary Shares and covered exercise/tax liability with 4,364 units of Ordinary Shares, increasing direct ownership by 12% to 29,282 units (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    1/8/26 9:01:55 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF DEV. OFFICER Naylor Stuart converted options into 37,500 units of Ordinary Shares and covered exercise/tax liability with 17,625 units of Ordinary Shares, increasing direct ownership by 3% to 643,166 units (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    1/8/26 9:00:30 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Financials

    Live finance-specific insights

    View All

    MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

    Clinically meaningful improvements in xerostomia symptoms measured by two different xerostomia PROs demonstrated across both unilaterally and bilaterally treated cohorts at 12 monthsIncreases in whole saliva flow rates observed post-treatment, providing objective evidence of biological activity, reaching the normal range in bilaterally treated participants by 2 months and persisting through the Month 12 assessmentAcross assessments, greater improvements observed in bilaterally treated participants compared to those treated unilaterally Early long-term follow-up data suggest durability of improvement to at least 3 years post-treatmentAAV2-hAQP1 appears safe and well tolerated at each dose te

    6/27/23 7:30:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023

    LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on the Company's AAV-hAQP1 clinical program for the treatment of grade 2/3 radiation-induced xerostomia (RIX) on Tuesday, June 27, 2023, at 8:00 a.m. ET. The presentation will include: 1) Data from the completed Phase 1 AQUAx clinical study for the 24 patients treated with AAV-hAQP1 in the unilateral and bilateral cohorts: Safety and tolerability12-month data for PRO assessments of xerostomia symptoms in the unilateral cohorts (n=12)12-month data for

    6/22/23 4:01:00 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

    Clinically meaningful improvements in xerostomia symptoms and disease burden reported in patient reported outcome (PRO) measures in both unilateral and bilateral cohortsIncreases in whole saliva flow rates were seen in both unilateral and bilateral cohorts Overall degree of improvement was greater in bilateral compared to unilateral cohorts AAV2-hAQP1 appears safe and well tolerated at each dose tested Webcast and conference call to be held today, December 13, 2022, at 8:00 a.m. ET LONDON and NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive clinical data from the ongoin

    12/13/22 7:30:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Leadership Updates

    Live Leadership Updates

    View All

    Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

    ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

    11/24/24 7:27:00 PM ET
    $LIAN
    $MGTX
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Landsdowne Labs Names Bryan Laulicht CEO

    Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design

    6/13/23 9:05:00 AM ET
    $MGTX
    $AMAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Pharmaceuticals

    MeiraGTx Appoints Debra Yu, MD to Board of Directors

    LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu currently serves as President and Chief Strategy Officer of LianBio, and previously served as LianBio's President and Chief Business Officer. Dr. Yu has more than 30 years of healthcare industry experience in business development, alliance management, investment banking and capital markets. She has held senior positions at Pfizer in its Worldwide Business Development organization and Labrador Advisors, LLC, where she advised numerous partnerships and licen

    4/27/22 8:00:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

    SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

    11/12/24 9:40:33 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

    SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

    10/18/24 4:47:58 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by MeiraGTx Holdings plc

    SC 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)

    8/14/24 7:21:27 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care